R&D partnership will identify and develop novel therapeutic targets for future therapies
News
Scottish Medicines Consortium agrees to use of Rinvoq
Therapy will now treat adults across Scotland with moderate rheumatoid arthritis
Novartis joins Cancer Research UK on rare cancers study
DETERMINE trial aims to discover if current treatments could benefit patients with other cancer types
Kidney Research UK concerned by NICE process
Organisation believes the guidance would leave renal patients with no effective treatment outside hospital
Positive results for Amphera’s MesoPher cell therapy
Treatment demonstrated significant survival data in addition to a sustained safety profile
Catalent completes cell therapy manufacturing facilities in Belgium
Facility represents one of the largest commercial-scale operations in the world
Novadip reveals results from severe bone non-union trial
Study involves candidate NVD-003 and the treatment of lower limb trauma
Laevoroc announces promising purine nucleoside phosphorylase data
Data supports LR 09 as a vital checkpoint inhibitor for treating leukaemia patients
ONWARD reveals ARC therapy spinal cord injury report
Implantable ARC therapy demonstrates potential to improve blood pressure regulation
AstraZeneca focuses on breast cancer care transformation
Data reinforces potential to deliver new standards across HER2-targetable breast cancer
Odimma Therapeutics and Touchlight announce clinical material collaboration
Partnership aims to progress personalised cancer therapy by incorporating doggybone DNA
LEO Pharma reveal positive results from delgocitinib research
Phase 3 clinical trial focuses on adults with moderate-to-severe chronic hand eczema
Spago Nanomedical begins endometriosis study
Clinical trial has received regulatory approval and involves endometriosis candidate SN132D
FDA grants fast-track designation for Istesso’s IPF candidate
The therapy has reduced inflammation and supported the remodelling of damaged bone
Valneva shares positive chikungunya vaccine results
99% of participants retained very high neutralising antibody levels 12 months after treatment
